STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES. STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).
Stocks highlighted in this watchlist include: $RXII, $ABUS, $ARWR, $FCSC
RXII: Float of 19.44 million shares with 8.67% short.
The November 13th NR continues to push this stock forward. The company has signed a collaborative research agreement with Gustave Roussy to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments. Gustave Roussy is a leading Comprehensive Cancer Centre in Europe.
ABUS: Float of 34.76 million shares with 1.5% short.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held on December 3 - 7, 2017 in Kona, Hawaii.
- December 5, 2017, 6:50pm - 7:10pm (HST), Shifting the Tide of Drug Development Towards HBV, NASH, and HCC: Battling Giant Killers
December 5, 2017, 3:30pm - 5:00pm (HST), Poster Session
- December 6, 2017, 12:00pm - 12:10pm (HST), Oral Abstract Session IV
ARWR: Float of 65.95 million shares with 4.81% short.
Arrowhead Pharmaceuticals Inc. (ARWR) will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference – New York, November 28-29, 2017. November 28, 9:30 a.m. EST – Christopher Anzalone Ph.D., Arrowhead president and chief executive officer will participate in a fireside chat presentation.
FCSC: Float of 14.0 million shares with 1.3% short.
No catalyst nearby but an nice reversal underway from a major drop in price over the past two months. Might be good for a Dead-cat bounce or potentially more.